black box warning for glp 1 agonists The Dark Side of Ozempic Advances in GLP-1 receptor agonists:

Universidad de Barcelona, Spain Despite recent advancements in the field of neuro-ophthalmology, the rising rates of neurological and ophthalmological conditions, mismatches between supply and demand of clinicians, and an aging population underscore the urgent need to explore new therapeutic approaches within the field

These dual access points mean more patients qualify for affordable weight loss therapy

Investigations to date have demonstrated promising safety and efficacy profiles [178]

Author Contributions H.A wrote main manuscript text, and created Tables 1 and 2

By July 31, 2025, the FDA had received 605 reports of adverse events tied to compounded semaglutide and 545 reports related to compounded tirzepatide

Some GLP-1 medications specifically injectable varieties also require refrigeration, much like insulin